×
-0.00199303135888508 -0.0156794425087109 -0.0278745644599303 -0.029616724738676 -0.0435540069686411 -0.0480836236933799 -0.054006968641115 -0.0662020905923346
Stockreport

Coherus BioSciences Provides Update on ‘619 IPR Institution Decision

Coherus BioSciences, Inc (CHRS)  More Company Research Source: GlobeNewswire
Last coherus biosciences, inc earnings: 11/8 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.coherus.com
PDF REDWOOD CITY, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office denied institution of all four of its petitions for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent 9,085,619 (“the ‘619 Patent”) related to AbbVie’s HUMIRA (adalimumab) formulation. “While we are disappointed by this outcome, we continue to develop and refine our legal strategies for addressing any patents, including formulation patents, that AbbVie may assert in District Court proceedings,” said Denny Lanfear, President and Chief Executive Officer of Coherus. About Coherus BioSciences, Inc.Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, [Read more]

IMPACT SNAPSHOT EVENT TIME: CHRS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
CHRS alerts
from News Quantified
Opt-in for
CHRS alerts

from News Quantified
Opt-in for
CHRS alerts

from News Quantified